Companies ink deal to develop OncoFAP-23

By staff writers

December 14, 2022 -- Philochem has signed agreements with Seibersdorf Laboratories and Isotopia Molecular Imaging to develop its lutetium-177 (Lu-177) OncoFAP-23 radiopharmaceutical for cancer treatment.

Lu-177 OncoFAP-23 is a new small molecule ligand under development for targeted radionuclide therapy in various cancers. It is designed to bind to fibroblast activation protein (FAP) in solid human malignancies where it delivers radiation to kill cancer cells while sparing normal tissue.

Under the agreements, Isotopia will supply Lu-177 to Seibersdorf Laboratories for development and manufacturing activities.

Copyright © 2022

To read this and get access to all of the exclusive content on create a free account or sign-in now.

Member Sign In:
MemberID or Email Address:  
Do you have a password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?
Sign in using your social networking account:
Sign in using your social networking